Celgene International Sarl (Nasdaq: CELG) today announced the publication of peer-reviewed data from a Phase II study of REVLIMID in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE